Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2011, Article ID 269515, 4 pages
Clinical Study

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

1Research Center for Skin Disease and Cutaneous Leishmaniasis, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
2Department of Social Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
3Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
4Young Researcher's Club, Islamic Azad university, Mashhad branch, Iran

Received 27 February 2011; Accepted 13 May 2011

Academic Editor: Aziz Ghahary

Copyright © 2011 Mohamad Javad Yazdanpanah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The first group was treated with oral zinc sulfate (10 mg/kg/day during 45 days period), and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). Acceptable cure after completing 45 days of followup occurred in 30.2% of lesions in first group, while this was 35.5% for the second group. There is not any significant difference between the two treatment groups ( ). Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without serious side effect.